top of page





Biomedical Science


Computer Software


Drug Delivery










Microelectromechanical Systems (MEMS)




Molecular Biology






Organic Chemistry



F. Brent Nix, J.D., M.Sc.


Brent Nix concentrates his practice in the field of intellectual property. His practice includes prosecuting patents in the biotech, medical device, and computer software space, as well as drafting and negotiating license agreements pertaining to intellectual property. His practice also includes conducting due diligence in support of mergers/acquisitions and IPOs, as well as conducting patentability studies, competitive landscape analysis, freedom to operate and invalidity analysis, and rendering opinions for the same.


While working as a patent agent, Mr. Nix received a Juris Doctor from Georgia State University School of Law. Prior to that, he received a B.S. from the University of North Carolina at Chapel Hill in 1999, and a M.Sc. in Bioinformatics from the Georgia Institute of Technology in 2003.  His undergraduate research was conducted in the Department of Biochemistry and Biophysics, where he studied the binding kinetics of the oncogenic protein Ras using fluorescence spectrophotometry.  Mr. Nix's graduate research was conducted in the Department of Biomedical Engineering’s lab of Biomolecular Engineering and Nanomedicine, where he worked on the design of a filtration-based protein microarray, and also assisted in the design and validation of dual FRET molecular beacons for in vivo monitoring of gene expression.


Prior to his graduate research, he worked at the University of North Carolina Hospital's Department of Pediatrics, Division of Infectious Disease, performing isolation and sequence analysis of various viral strains including coxsackievirus, rhinovirus, poliovirus, and influenza.


The breadth of his experience through his academic and professional career have allowed him to gain practical experience with a wide range of technologies.  A representative list of technology areas in which Mr. Nix holds technical and/or work experience is provided below.

  • Gene editing enzymes and corresponding expression and delivery constructs

  • Single cell analysis systems and assays

  • NGS technologies and assay platforms

  • Microfluidic devices for various ‘omics-related applications

  • Liquid biopsy, exosome, and cfDNA-based detection systems and assays

  • 3D culture devices and related scaffold and support materials

  • Diagnostic systems and constructs for various disease and microbial detection purposes, including amplification-, sequencing-, and probe-based assays and imaging modalities

  • Epigenetic assays and related constructs

  • Particle and viral-based delivery systems

  • Live cell imaging and sampling technologies

  • Xenograft models

  • Adoptive cell transfer and CAR T therapies

  • Vaccine and peptide-based therapeutics for neurodegenerative, cancer, autoimmune, and ocular diseases

  • Small molecule therapeutics for cancer, neurodegenerative, autoimmune and ocular diseases

  • Computer based methods for single cell analysis, imaging based classification, antigen prediction, and HLA and TCR typing


  • Santangelo PJ, Nix B, Tsourkas A, Bao G (2004) Dual FRET molecular beacons for mRNA detection in living cells. Nucleic Acids Research 32(6):e57

  • Lin S, Shi Q, Nix FB, Styblo M, Beck MA, Herbin-Davis KM, Hall LL, Simeonsson JB, Thomas DJ (2002) A Novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. Journal of Biological Chemistry 273(13): 10795-10803



  • J.D., Georgia State University School of Law, 2014

  • M.S., Bioinformatics, Georgia Institute of Technology, 2003

  • B.S., Biology, University of North Carolina at Chapel Hill, 1999


Admitted to Practice

  • United States Patent and Trademark Office

  • Georgia Bar


Direct:  404.665.3099

Please reload

bottom of page